Allergan plc (AGN) Stake Raised by Affinity Investment Advisors LLC

Affinity Investment Advisors LLC lifted its position in shares of Allergan plc (NYSE:AGN) by 4.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 62,184 shares of the company’s stock after buying an additional 2,875 shares during the quarter. Affinity Investment Advisors LLC’s holdings in Allergan were worth $10,172,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. California Public Employees Retirement System increased its position in shares of Allergan by 3.2% during the fourth quarter. California Public Employees Retirement System now owns 718,800 shares of the company’s stock worth $117,581,000 after buying an additional 22,526 shares during the period. Boston Family Office LLC increased its position in shares of Allergan by 12.1% during the fourth quarter. Boston Family Office LLC now owns 4,622 shares of the company’s stock worth $756,000 after buying an additional 500 shares during the period. SFE Investment Counsel acquired a new stake in shares of Allergan during the fourth quarter worth $240,000. Hyman Charles D acquired a new stake in shares of Allergan during the fourth quarter worth $206,000. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its position in shares of Allergan by 1.2% during the fourth quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 50,854 shares of the company’s stock worth $8,652,000 after buying an additional 595 shares during the period. Institutional investors own 80.23% of the company’s stock.

In other Allergan news, Director Christopher J. Coughlin acquired 10,000 shares of the company’s stock in a transaction on Tuesday, December 5th. The shares were purchased at an average cost of $163.30 per share, with a total value of $1,633,000.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider William Meury sold 11,807 shares of the firm’s stock in a transaction on Friday, December 1st. The shares were sold at an average price of $173.89, for a total transaction of $2,053,119.23. The disclosure for this sale can be found here. Insiders acquired 17,630 shares of company stock worth $2,890,057 over the last ninety days. Insiders own 0.36% of the company’s stock.

Several research firms have recently weighed in on AGN. Leerink Swann increased their price objective on shares of Allergan from $237.00 to $242.00 and gave the stock an “outperform” rating in a research report on Wednesday. Piper Jaffray Companies set a $227.00 price objective on shares of Allergan and gave the stock a “hold” rating in a research report on Friday, October 13th. Royal Bank of Canada restated an “outperform” rating and issued a $250.00 price target (down from $277.00) on shares of Allergan in a report on Thursday, October 19th. They noted that the move was a valuation call. Vetr cut shares of Allergan from a “buy” rating to a “hold” rating and set a $180.97 price target for the company. in a report on Wednesday, January 10th. Finally, Wells Fargo & Co restated an “outperform” rating and issued a $245.00 price target (down from $258.00) on shares of Allergan in a report on Thursday, November 2nd. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and fourteen have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $227.23.

Shares of Allergan plc (AGN) opened at $164.20 on Friday. Allergan plc has a twelve month low of $160.07 and a twelve month high of $256.80. The company has a market cap of $56,670.00, a price-to-earnings ratio of -13.69, a price-to-earnings-growth ratio of 1.24 and a beta of 1.19. The company has a quick ratio of 1.08, a current ratio of 2.04 and a debt-to-equity ratio of 0.41.

Allergan (NYSE:AGN) last released its quarterly earnings data on Tuesday, February 6th. The company reported $4.86 earnings per share for the quarter, beating analysts’ consensus estimates of $4.74 by $0.12. Allergan had a negative net margin of 26.32% and a positive return on equity of 8.28%. The firm had revenue of $4.33 billion for the quarter, compared to analyst estimates of $4.28 billion. During the same period last year, the firm earned $3.90 earnings per share. The business’s quarterly revenue was up 12.0% compared to the same quarter last year. equities analysts predict that Allergan plc will post 15.41 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This piece was reported by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this piece on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The original version of this piece can be viewed at https://sportsperspectives.com/2018/02/09/allergan-plc-agn-stake-raised-by-affinity-investment-advisors-llc.html.

Allergan Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan plc (NYSE:AGN).

Institutional Ownership by Quarter for Allergan (NYSE:AGN)

Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply